CT38 modulates these same functions in ME/CFS patients, exacerbating them for Cmax >0.25 ng/ml while improving them for Cmax <0.25 ng/ml, respectively, consistent with CRFR2 upregulation and endocytosis (Figure 6). The gene discussed is FTHL17; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.